- Study: Participation in diabetes education associated with greater ability to self-manage
- FDA approves Novo Nordisk's Novoeight for hemophilia A
- Novo Nordisk launches new insulin device
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
PRINCETON, N.J. — Danish drug maker Novo Nordisk has received the Corporate Leadership Award from the National Hemophilia Foundation in response to its research and development efforts for the disease, the company said Friday.
Novo Nordisk president Jurek Gruhn accepted the award at the NHF’s Inaugural Spring Soiree Benefit in New York Thursday. Novo Nordisk makes NovoSeven RT (coagulation factor VIIa [recombinant], room temperature stable), used to treat hemophilia A and B.
“We are honored by this recognition and are pleased to support NHF in its continued efforts to build a national movement toward better patient care in hemophilia,” Novo Nordisk corporate VP biopharmaceuticals Eddie Williams said. “We look forward to many more years of continued research, innovative treatments and initiatives to help improve the lives of patients.”
The company said it was dedicated to making advancements in strengthening the understanding of hemophilia in the broader society, improving access to diagnosis and patient care, and advancing treatment through innovation. It also supports SevenSecure, a program that offers access to financial, educational and medical support and provides funding for the Inhibitor Education Summits, designed for people living with hemophilia.